Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature
- 17 June 2004
- journal article
- review article
- Published by Springer Nature in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 130 (9) , 497-513
- https://doi.org/10.1007/s00432-004-0572-9
Abstract
Molecular markers (biomarkers) for hepatocellular carcinoma (HCC) metastasis and recurrence could provide additional information to that gained from traditional histopathological features. A large number of biomarkers have been shown to have potential predictive significance. One important aspect of this is to detect the transcripts of tumor-associated antigens (such as AFP, MAGEs, and CK19), which are proposed as predictive markers of HCC cells disseminated into the circulation and for metastatic recurrence. Another important aspect is to analyze the molecular markers for cellular malignancy phenotype, including DNA ploidy, cellular proliferation index, cell cycle regulators, oncogenes, and tumor suppressors (especially p53 gene), as well as telomerase activity. Molecular factors involved in the process of HCC invasion and metastasis, including adhesion molecules (E-cadherin, catenins, ICAM-1, laminin-5, CD44 variants, osteopontin), proteinases responsible for the degradation of extracellular matrix (MMPs, uPA system), as well as angiogenesis regulators (such as VEGF, intratumor MVD), have also been shown to be potential predictors for HCC metastatic recurrence and clinical outcomes. One important new trend is to widely delineate biomarkers with genomic and proteomic expression with reference to predicting metastatic recurrence, molecular diagnosis, and classification, which has been drawing more attention recently. Body fluid (particularly blood and urine) testing for biomarkers is easily accessible and more useful in clinical patients. The prognostic significance of circulating DNA in plasma or serum and its genetic alterations is another important direction. More attention should be paid to these areas in the future. As understanding of tumor biology deepens, more and more new biomarkers with high sensitivity and specificity for HCC metastatic recurrence could be found and routinely used in clinical assays. However, the combination of the pathological features and some of the biomarkers mentioned above seems to be more practical up to now.Keywords
This publication has 99 references indexed in Scilit:
- Detection and Prediction of Micrometastasis in the Lymph Nodes of Patients With pN0 Gastric CancerAnnals of Surgical Oncology, 2001
- A comparative study of the clinicopathological significance of E-cadherin and catenins (α, β, γ) expression in the surgical management of oral tongue carcinomaZeitschrift für Krebsforschung und Klinische Onkologie, 2001
- Reck Gene Expression in Hepatocellular Carcinoma: Correlation With Invasion–Related Clinicopathological Factors and Its Clinical SignificanceHepatology, 2001
- Reduced CD44 standard expression is associated with tumour recurrence and unfavourable outcome in differentiated thyroid carcinomaThe Journal of Pathology, 2000
- Altered expression of E-cadherin in breast cancerEuropean Journal Of Cancer, 2000
- The prognostic value of p53 and c-erb b-2 immunostaining is overrated for patients with lymph node negative breast carcinomaCancer, 2000
- Reduced E-Cadherin Expression and Enlargement of Cancer Nuclei Strongly Correlate with Hematogenic Metastasis in Colorectal AdenocarcinomaScandinavian Journal of Gastroenterology, 2000
- TP53Mutation is an Independent Prognostic Marker for Poor Outcome in Both Node-negative and Node-positive Breast CancerActa Oncologica, 2000
- Hepatitis viral status in patients undergoing liver resection for hepatocellular carcinomaBritish Journal of Surgery, 1999
- Presence of α-fetoprotein mRNA in blood correlates with outcome in patients with hepatocellular carcinomaJournal of Hepatology, 1999